Biocon Completes Rs 4,150 Crore Equity Fundraise via QIP
Filing Summary
Biocon Limited has concluded a Qualified Institutions Placement (QIP), raising Rs 4,150 crore (approximately USD 460 million). The QIP involved the issuance of 112,664,585 equity shares at Rs 368.35 per share. The funds will be used primarily to acquire Mylan Inc.’s stake in Biocon Biologics Limited and repay related debt. The QIP attracted interest from 39 investors, including domestic mutual funds and foreign institutional investors. The transaction is part of Biocon’s strategy to make Biocon Biologics a wholly owned subsidiary, with completion expected by March 31, 2026.
Biocon Limited has successfully completed a Qualified Institutions Placement (QIP), raising Rs 4,150 crore, which is approximately USD 460 million. The placement involved the issuance of 112,664,585 equity shares, each with a face value of Rs 5, to eligible qualified institutional buyers. The issue price was set at Rs 368.35 per equity share, which includes a premium of Rs 363.35 per share. The QIP opened on January 12, 2026, and closed on January 14, 2026.
The proceeds from the QIP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for acquiring its shareholding in Biocon Biologics Limited. This includes the repayment of debt availed for this purpose. The transaction is part of Biocon’s strategic move to acquire all remaining minority shareholdings in Biocon Biologics, thereby making it a wholly owned subsidiary. The company has also planned to use the funds for the repayment of debt related to the acquisition of compulsory convertible debentures held by Edelweiss and for general corporate purposes.
The QIP attracted significant interest from a diverse group of investors, including domestic mutual funds, domestic insurance companies, and foreign institutional investors. A total of 39 investors participated in the QIP, with allocations made to all. Notable participants included SBI Mutual Fund, ICICI Prudential Mutual Fund, Mirae Asset Mutual Fund, Birla Mutual Fund, HDFC Life Insurance, ICICI Prudential Life Insurance, and JPMorgan Asset Management.
The company received shareholders’ approval for the fundraise during an Extra-Ordinary General Meeting held on December 31, 2025. The Book Running Lead Managers for the QIP were Kotak Mahindra Capital Company Limited, HSBC Securities and Capital Markets (India) Private Limited, J.P. Morgan India Private Limited, and Morgan Stanley India Company Private Limited. Legal counsel for the company was provided by Shardul Amarchand Mangaldas & Co., while Linklaters Singapore Pte. Ltd. and JSA Advocates & Solicitors served as legal counsels to the Book Running Lead Managers.
The integration of Biocon Biologics as a wholly owned subsidiary is expected to be completed by March 31, 2026. This move is aligned with Biocon’s strategy to strengthen its position in therapeutic areas such as diabetes, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, generics, and peptides.
Biocon Limited is an innovation-led global biopharmaceutical company focused on enhancing affordable access to complex therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and key global markets. Biocon is committed to advancing healthcare through its pipeline of promising novel assets in immunotherapy.